Cargando…

Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells

Over 225 000 new cases of ovarian cancer are diagnosed each year. Symptoms are often vague, so most cases are detected when the disease is at an advanced stage. There is a need to find new drugs which will be able to treat ovarian cancer effectively. One of the most promising antineoplastic agents i...

Descripción completa

Detalles Bibliográficos
Autores principales: Marczak, Agnieszka, Denel, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268992/
https://www.ncbi.nlm.nih.gov/pubmed/25520572
http://dx.doi.org/10.5114/wo.2014.43153
_version_ 1782349312130285568
author Marczak, Agnieszka
Denel, Marta
author_facet Marczak, Agnieszka
Denel, Marta
author_sort Marczak, Agnieszka
collection PubMed
description Over 225 000 new cases of ovarian cancer are diagnosed each year. Symptoms are often vague, so most cases are detected when the disease is at an advanced stage. There is a need to find new drugs which will be able to treat ovarian cancer effectively. One of the most promising antineoplastic agents is trabectedin (Yondelis), derived from the marine tunicate Ecteinascidia turbinata, approved by the European Union in July 2007 for the treatment of soft-tissue sarcomas. This drug shows a mechanism of action based on the inhibition of the nucleotide excision repair system. Trabectedin shows anti-tumour activity in vitro and in vivo in ovarian, breast, prostate, renal, melanoma and non-small cell lung cancer cell lines. Trabectedin in combination with pegylated liposomal doxorubicin demonstrates synergistic antineoplastic activity.
format Online
Article
Text
id pubmed-4268992
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-42689922014-12-17 Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells Marczak, Agnieszka Denel, Marta Contemp Oncol (Pozn) Review Over 225 000 new cases of ovarian cancer are diagnosed each year. Symptoms are often vague, so most cases are detected when the disease is at an advanced stage. There is a need to find new drugs which will be able to treat ovarian cancer effectively. One of the most promising antineoplastic agents is trabectedin (Yondelis), derived from the marine tunicate Ecteinascidia turbinata, approved by the European Union in July 2007 for the treatment of soft-tissue sarcomas. This drug shows a mechanism of action based on the inhibition of the nucleotide excision repair system. Trabectedin shows anti-tumour activity in vitro and in vivo in ovarian, breast, prostate, renal, melanoma and non-small cell lung cancer cell lines. Trabectedin in combination with pegylated liposomal doxorubicin demonstrates synergistic antineoplastic activity. Termedia Publishing House 2014-06-18 2014 /pmc/articles/PMC4268992/ /pubmed/25520572 http://dx.doi.org/10.5114/wo.2014.43153 Text en Copyright © 2014 Termedia http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Marczak, Agnieszka
Denel, Marta
Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells
title Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells
title_full Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells
title_fullStr Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells
title_full_unstemmed Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells
title_short Trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells
title_sort trabectedin as a single agent and in combination with pegylated liposomal doxorubicin – activity against ovarian cancer cells
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268992/
https://www.ncbi.nlm.nih.gov/pubmed/25520572
http://dx.doi.org/10.5114/wo.2014.43153
work_keys_str_mv AT marczakagnieszka trabectedinasasingleagentandincombinationwithpegylatedliposomaldoxorubicinactivityagainstovariancancercells
AT denelmarta trabectedinasasingleagentandincombinationwithpegylatedliposomaldoxorubicinactivityagainstovariancancercells